Literature DB >> 1985791

Influence of major histocompatibility complex class I and II antigens on survival in colorectal carcinoma.

P Möller1, F Momburg, K Koretz, G Moldenhauer, C Herfarth, H F Otto, G J Hämmerling, P Schlag.   

Abstract

HLA-A,B,C and HLA-D molecules present antigenic peptides to the antigen-specific receptor of autologous T-lymphocytes. T-cell-mediated host-versus-tumor response might therefore depend on the presence of these molecules on tumor cells, although the absence of HLA-A,B,C determinants on a cell has been shown to increase its susceptibility to lysis by natural killer cells. To investigate whether the presence or absence of HLA-A,B,C and/or HLA-DR in colorectal carcinoma influences relapse rate and time of tumor-related death, 152 patients who underwent putatively curative surgical treatment were surveyed for a maximum of 65 months (mean, 48 months). As determined by immunohistochemistry, aberrant reduction or loss of HLA-A,B,C/beta 2-microglobulin molecules was more frequent in tumors of the proximal colon than of the rectosigmoid (P = 0.032) and in mucinous carcinomas than in nonmucinous ones (P = 0.022). An abnormal induction of the HLA-D-associated invariant chain (Ii) was more frequent in Dukes' A and B than in stage C (P = 0.046). Reduction/loss of HLA-A,B,C/beta 2-microglobulin was correlated with the absence of HLA-DR (P = 0.024) and Ii (P = 0.005). In contrast to the prognostic role of tumor stage and grade, the presence versus the absence of HLA-A,B,C/beta 2-microglobulin and HLA-DR/Ii molecules was not correlated with recurrence rate or survival. We conclude that in spite of an increasing amount of experimental data suggesting the contrary, the status of HLA-A,B,C and HLA-DR expression in colorectal carcinoma seems to be irrelevant in vivo, regarding survival and growth of residual tumor cells after putatively curative resection of the initial tumor burden.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1985791

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  24 in total

Review 1.  Cell surface molecules and their prognostic values in assessing colorectal carcinomas.

Authors:  J Haier; M Nasralla; G L Nicolson
Journal:  Ann Surg       Date:  2000-01       Impact factor: 12.969

2.  Sporadic loss of leucocyte-function-associated antigen-3 (LFA-3) in colorectal carcinomas.

Authors:  K Koretz; P Schlag; P Möller
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1991

3.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 4.  The bodies fight against cancer: is human leucocyte antigen (HLA) class 1 the key?

Authors:  Arfon G M T Powell; Paul G Horgan; Joanne Edwards
Journal:  J Cancer Res Clin Oncol       Date:  2012-03-18       Impact factor: 4.553

5.  Mitomycin C directly augments the expression of HLA-DR antigen in a gastric carcinoma cell line.

Authors:  H Inoue; M Adachi; S Arinaga; H Ueo; T Akiyoshi
Journal:  Med Oncol       Date:  1994       Impact factor: 3.064

6.  CD74 is a survival receptor on colon epithelial cells.

Authors:  Nitsan Maharshak; Sivan Cohen; Frida Lantner; Gili Hart; Lin Leng; Richard Bucala; Idit Shachar
Journal:  World J Gastroenterol       Date:  2010-07-14       Impact factor: 5.742

7.  Activation by interferon-gamma of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas.

Authors:  I Donnellan; J Cantrill; I Fraser; A Morris
Journal:  Clin Mol Pathol       Date:  1995-02

8.  Interactions between interferon gamma and retinoic acid with transforming growth factor beta in the induction of immune recognition molecules.

Authors:  R Darley; A Morris; J Passas; W Bateman
Journal:  Cancer Immunol Immunother       Date:  1993-07       Impact factor: 6.968

9.  T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.

Authors:  P A Lando; M Dohlsten; G Hedlund; E Akerblom; T Kalland
Journal:  Cancer Immunol Immunother       Date:  1993       Impact factor: 6.968

10.  A rare mediastinal tumour presenting with systemic effects due to IL-6 and tumour necrosis factor (TNF) production.

Authors:  K A Davies; A P Cope; J B Schofield; C Q Chu; J C Mason; T Krausz; P Smith; A M Denman; M J Walport
Journal:  Clin Exp Immunol       Date:  1995-01       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.